Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FB418 in Healthy Adult and Elderly Subjects
NCT05995782Phase 1Recruiting
- Sponsor
- 1ST Biotherapeutics
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) comparing FB418 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2023; status: recruiting.
02
Drugs
FB-418
03
Conditions
Parkinson's disease (PD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05995782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995782.